Proactive investor today

Zelda Therapeutics to supply its cannabis medicine to cancer patients in Newcastle trialZelda will be one of several suppliers in the clinical trial seeking to enrol up to 600 advanced cancer patients.The agreement will generate revenues and raise awareness of Zelda-branded productsZelda Therapeutics Ltd (ASX:ZLD) has entered into an agreement to commercially supply an oil-based cannabis medicine formulation for the CARE NSW Clinical Trial involving up to 600 patients.The CARE NSW Clinical Trial will be assessing safety, tolerability and efficacy of different cannabis medicine formulations to provide symptom relief in advanced cancer patients.The commercial supply agreement will generate revenuesZelda’s managing director Richard Hopkins said: “We’re delighted for the opportunity to supply investigational product in the CARE NSW trial.“The focus on studying cannabis as a strategy to potentially alleviate symptoms in advanced cancer patients is very much aligned to our strategic interests in this area.“The commercial supply agreement also represents a significant milestone for our shareholders, as it is expected to generate the company’s first revenues from Zelda-branded TGA-TG093 compliant products.“This is an important step towards commercialisation of Zelda’s own clinically validated products for sleep, chronic pain and anxiety, which the Zelda is expected to launch from 2020."Trial based at University of NewcastleThe agreement is with the National Health and Medical Research Council (NHMRC)-funded Australian Centre for Clinical Cannabinoid Research Excellence (ACRE) based at the University of Newcastle.The trial is formally known as the Cannabinoids for Symptom Control in Advanced Cancer, An Open Label Prospective Clinical Trial in NSW (CARE NSW).Zelda is one of several suppliers selected to supply investigation product for the trial under a commercial contract.Each patient will be prescribed a cannabis medicine from a defined selection of products currently available in Australia that are compliant with TG093 and GMP regulations.The choice of study drug will be guided by the patient’s primary index symptoms and at the discretion of the doctor and supply.Quick facts: Zelda Therapeutics LtdPrice: 0.07 AUDASX:ZLDMarket:ASXMarket Cap:$53.12 mFollowJul '19Oct '190.040.060.080.1024MZoom1m3m6m1yFromMay 15, 2019ToNov 15, 2019Highcharts.comWeek from Monday, Nov 4, 2019● Share price: 0.0682● Volume: 1 334 880View company profileAdd related topics to MyProactiveHealth Cannabis Small caps Zelda Therapeutics LtdSign up for NewsletterCreate your account: sign up and get ahead on news and eventsNO INVESTMENT ADVICEProactive Investors Australia Pty Ltd ACN 132 787 654 (the Company, we or us) provides you with access to the content set out above, including any news, quotes, information, data, text, reports, ratings, opinions,...FOR OUR FULL DISCLAIMER CLICK HEREMost readMiningTietto Minerals to continue aggressive resource definition campaign at...3 days agoFinanceAfterpay analysts weigh in after yesterday’s AGM trading update1 day, 9 hours agoHealthZelda Therapeutics banks $982,000 R&D cash ahead of Ilera Therapeutics...4 days, 6 hours agoTechPure Minerals signs MoU with Blue Energy for TECH Project gas supply3 days agoInvestor deep diveZelda Therapeutics and Ilera Therapeutics plan merger to "disrupt medicinal cannabis markets"read more >More on this storyHealthZelda Therapeutics banks $982,000 R&D cash ahead of Ilera...4 days, 6 hours agoHealthZelda Therapeutics completes enrolment for insomnia trial1 week, 1 day agoHealthZelda Therapeutics and Ilera Therapeutics plan merger to "disrupt...on 9/10/19HealthZelda Therapeutics in trading halt ahead of transaction with US...on 8/10/19Watch06.52Ilera Healthcare deal is 'one piece of the puzzle' for Zelda Therapeutics in...Zelda Therapeutics Ltd (ASX:ZLD, OTCBB:ZLDAF) managing director Dr Richard Hopkins speaks to Proactive Investors about the medical cannabis researcher's binding heads of agreement (HoA) with US-based medicinal cannabis company Ilera Healthcare LLC. The deal complements a number of...on 12/3/1900.13HealthZelda Therapeutics poised to 'value add all the way from clinical...on 3/12/1804.50HealthZelda enters rapidly-growing German market with product...on 10/9/1804.32HealthZelda Therapeutics ready to test 'entourage effect' hypothesis in...on 18/6/1811.31HealthZelda Therapeutics "ahead of the pack" in gaining first-mover...on 4/5/18Editor's picksMiningMacarthur Minerals attracts pre-listing buy recommendation and...2 hours, 46 minutes agoMiningHavilah Resources shareholders show vote of faith with strong...5 hours, 5 minutes agoMiningGalena Mining managing director builds on holding through...6 hours, 46 minutes agoMiningCanyon Resources sees benefits in two-stage development for...6 hours, 55 minutes agoMiningPantoro reveals outstanding drill results up to 94.2 g/t gold at...1 day agoEnergyFAR Ltd to pursue conventional bank lending option to finance SNE...1 day ago01.00FinanceFull interview: Jindalee Resources McDermitt project confirmed as...1 day, 1 hour agoMiningHavilah Resources leveraged to first diamond hole underway at...1 day, 7 hours agoMiningTwenty Seven Co has drill spinning at Rover’s priority gold/VMS...2 days, 3 hours agoMiningWest Wits Mining clarifying matters raised in WBP Mining Right...2 days, 6 hours agoAdd Zelda Therapeutics Ltd to ale